UnitedHealth Group Incorporated

UnitedHealth Group Incorporated (UNH) Market Cap

UnitedHealth Group Incorporated has a market capitalization of $376.34B.

Price: $414.40

-7.07 (-1.68%)

Market Cap: 376.34B

NYSE · time unavailable

CEO: Stephen J. Hemsley

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 1984-10-17

Website: https://www.unitedhealthgroup.com

UnitedHealth Group Incorporated (UNH) - Company Information

Market Cap: 376.34B|Sector: Healthcare

Company Profile

UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment provides a wide array of health benefit plans and consumer-focused services. These offerings cater to a broad spectrum of clients, including large national corporations, public sector employers, mid-sized and small businesses, and individual consumers. It also delivers specialized health coverage and wellness programs tailored for individuals aged 50 and older, addressing their needs for preventive and acute care, chronic disease management, and other age-specific health issues. This division further encompasses Medicaid plans, children's health insurance, dental benefits, and various hospital and clinical services. Optum Health focuses on delivering direct healthcare solutions and management services. It facilitates access to networks of specialist care providers, offers health management programs, direct care delivery, consumer engagement initiatives, and financial services. Its diverse clientele includes individuals (served directly through care systems), employers, insurance payers, and government organizations. Optum Insight specializes in providing technology, information, and consulting services to the healthcare industry. Its offerings include software and data products, advisory consulting arrangements, and outsourced managed services. Clients span hospital systems, physicians, health plans, governmental bodies, life sciences companies, and other relevant organizations. Finally, Optum Rx handles the company's pharmaceutical care services. This segment manages retail pharmacy networks, provides home prescription delivery, and offers specialty and compounding pharmacy capabilities. Leveraging its purchasing power and clinical expertise, Optum Rx also develops advanced programs related to step therapy, formulary management, medication adherence, and integrated disease and drug therapy management. UnitedHealth Group Incorporated, founded in 1977, has its corporate headquarters located in Minnetonka, Minnesota.

Analyst Sentiment

79%
Strong Buy

From 29 Active Polls

1Y Forecast: $473.89

▲ +14.4% Potential Upside

Consensus Target Metrics

Low Bound

$373

Median

$491

High Bound

$529

Average

$474

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$473.89
▲ +14.36% Upside
Low Target
$373.00
-10% Risk
Median Target
$491.00
18% Mid
High Target
$529.00
28% Max
Consensus
Buy
43 / 52 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)376,335376,560246,237300,400313,532283,893480,803468,932539,660
Enterprise Value ($M)418,195418,420296,153354,424366,458334,490531,357520,524585,270
Price to Earnings Ratio (P/E)26.6517.179.807502.5033.3320.7418.9521.1522.28
Price/Earnings-to-Growth Ratio (PEG)61.70157220.4424.0811.142.1811.21
Price to Sales Ratio (P/S)0.843.362.202.652.772.544.394.655.35
Price to Book Ratio (P/B)3.593.602.523.193.273.005.065.065.71
Price to Free Cash Flow Ratio (P/FCF)15.9336.7330.221877.5062.0245.05105.49321.8541.66
Enterprise Value to Sales (EV/Sales)3.732.653.133.243.004.855.165.81
Enterprise Value to EBITDA (EV/EBITDA)16.2346.6529.35258.5268.7454.0152.2758.9260.16
Debt to Equity Ratio1.620.700.800.830.840.840.860.830.83

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 UNITEDHEALTH GROUP INC (UNH) — Investment Overview

🧩 Business Model Overview

UnitedHealth Group operates an integrated health services platform spanning insurance and healthcare services. On the payer side, UnitedHealthcare earns premiums and is accountable for member outcomes and costs through managed-care contracting (with physicians, hospitals, and other providers) and benefit plan administration. On the services side, Optum supplies capabilities across pharmacy benefit management, care delivery, analytics, and other healthcare services, which feed into utilization management and care coordination.

The economic logic is that scale in enrollment and provider contracting improves cost and care efficiency, while Optum’s services supply tools (clinical management, analytics, and pharmacy leverage) that can tighten medical cost trend. This integration creates a value chain where underwriting discipline and service execution reinforce each other, strengthening member retention and employer plan stickiness.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by:

  • Premiums/capitation and administrative fees from health plans (payer segment). This stream is largely recurring, tied to membership and benefit design.
  • Fees for healthcare services across Optum (services segment), including pharmacy benefit administration and care delivery-related revenues. This mix tends to be more recurring and contract-driven than pure one-time transactions.

Margin drivers center on:

  • Medical cost management (discipline around utilization, network design, and care pathways), which influences profitability in the payer segment.
  • Pharmacy and services efficiency (formulary strategy, pharmacy network leverage, and operational throughput), which influences incremental margins at Optum.
  • Operating leverage from shared analytics and workflow capabilities across the integrated ecosystem.

🧠 Competitive Advantages & Market Positioning

UNH’s core moat is an integrated ecosystem that combines payer scale with high-value services, supported by switching costs, data/analytics barriers, and cost advantages.

  • Integrated ecosystem (integrated ecosystem moat): Optum’s clinical and operational tools—analytics, pharmacy management, and care delivery—improve utilization control and care coordination. Competitors that operate as standalone payers or standalone services providers face higher coordination costs and less end-to-end optimization.
  • Switching costs and contracting inertia (switching costs moat): Large employers, government programs, and provider networks develop operational and reimbursement alignment with existing plan designs. Changing vendors requires renegotiation, administrative reconfiguration, and performance rebuilding, which tends to support retention.
  • Cost and scale advantages (cost advantages moat): Enrollment scale enhances negotiating leverage with providers and pharmacies. The ability to manage risk and trend through analytics and targeted care programs supports more consistent earnings quality than less diversified peers.
  • High barriers to entry (barriers through scale, compliance, and risk management): Building the actuarial, regulatory, and operational infrastructure to manage member risk at scale is non-trivial, especially within complex government programs.

Competitive benchmarking (industry focus vs. peers):

  • CVS Health (payer + PBM + retail/health services exposure): Like UNH, CVS spans multiple healthcare functions. UNH’s differentiation is the emphasis on an end-to-end managed-care ecosystem with Optum’s analytics and care delivery integrated into the payer workflow.
  • Humana (predominantly managed care): Humana’s strengths concentrate more heavily in insurance execution and Medicare-focused membership. UNH’s services footprint adds another channel to influence utilization and margins beyond underwriting alone.
  • Cigna (managed care + services footprint): Cigna operates across payer and services. UNH’s scale across services—particularly pharmacy and analytics-driven care management—supports a broader platform approach to cost and outcomes management.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular healthcare demand and structural shifts in how care is delivered and paid:

  • Demographic tailwinds: Aging populations increase enrollment in Medicare and raise the need for chronic disease management and coordinated care.
  • Ongoing shift toward managed care and value-based approaches: Payers that can manage utilization risk and standardize care pathways typically benefit as reimbursement moves away from pure fee-for-service incentives.
  • Expansion of Optum services into higher-value segments: Growth opportunities exist in care delivery, pharmacy services, and analytics-driven programs that reduce avoidable utilization while improving care quality.
  • Healthcare spending complexity: Higher care complexity strengthens demand for administrative efficiency, clinical management, and outcomes measurement—areas where integrated players can deploy data and operating workflows at scale.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement risk: Changes to Medicare Advantage and Medicaid rate-setting, risk adjustment, and benefit requirements can pressure profitability and forecastability.
  • Medical cost trend and risk selection: Higher-than-expected utilization, adverse selection, or changes in provider pricing can widen the gap between estimated and realized costs.
  • PBM and pricing policy scrutiny: Pharmacy-related regulation and payer-provider reimbursement dynamics can affect services economics and formulary strategies.
  • Provider market dynamics: Provider consolidation and pricing power can increase cost pressure; network adequacy and contracting execution become more consequential.
  • Operational and cybersecurity risk: Integrated platforms rely on robust systems, data governance, and secure operations; disruptions can impair service quality and lead to regulatory exposure.
  • Execution risk in care delivery: Scaling care delivery models requires sustained quality, staffing, and cost discipline to avoid margin dilution.

📊 Valuation & Market View

Healthcare managed-care platforms are typically valued based on earnings durability, member growth and retention, and improvement in medical cost management, rather than pure top-line expansion. Market pricing often reflects the credibility of:

  • Medical loss ratio discipline and the ability to manage utilization and provider reimbursement over cycles.
  • Services margin expansion driven by Optum scale, operating leverage, and pharmacy/analytics effectiveness.
  • Regulatory sensitivity—the perceived likelihood that reimbursement and policy changes remain within a manageable range.

The valuation “needle movers” are largely tied to forecast accuracy for risk adjustment and medical cost trend, plus the consistency of services execution that converts integrated capabilities into stable cash generation.

🔍 Investment Takeaway

UnitedHealth Group combines a large managed-care membership base with a scaled services platform to form an integrated ecosystem. The principal moat is structural: switching costs, cost advantages from scale, and end-to-end coordination through analytics and services. With demographic-driven demand and continued migration toward managed and value-based care, the long-term thesis rests on sustained utilization management, resilient regulatory navigation, and ongoing Optum execution that reinforces payer economics.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for UNH.

zacks.com2026-07-31

UnitedHealth vs. Centene: Which Managed Care Stock Is the Better Buy?

UNH's diversified platform, AI expansion and Optum momentum strengthen its long-term outlook, making it the stronger managed care pick over CNC.

247wallst.com2026-07-31

Medicare Advantage Insurers Are Redrawing the Map for 2027. Members Find Out by Letter This Fall.

Millions of Medicare Advantage members will open a letter this fall that could quietly close doors they assume will always stay open. What insurers have already decided for 2027 and what enrollees do next could cost thousands of dollars or make coverage impossible to find.

zacks.com2026-07-31

Wall Street Analysts Think UnitedHealth (UNH) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

zacks.com2026-07-29

UnitedHealth's Cost-Control Story is Gaining Momentum: Time to Buy?

UNH's improving cost control, lower medical costs and higher 2026 outlook are boosting confidence as its profitability recovery gains traction.

zacks.com2026-07-29

Buy These 3 Blue-Chip Stocks After Strong Q2 2026 Earnings Results

MMM, TRV and UNH posted strong Q2 results, with higher guidance, investment strength and growth drivers supporting their 2026 outlooks.

businesswire.com2026-07-29

UnitedHealth Group Partners with UT Health Sciences to Expand Health Hubs to More Communities Across Tennessee

--(BUSINESS WIRE)--UnitedHealth Group today announced new support to expand the University of Tennessee Health Sciences' health hub model statewide, helping more Tennesseans access preventive care, chronic condition support and local health resources in their communities. The new support includes a $4 million commitment, with funding from the United Health Foundation and technical assistance from UnitedHealth Group, to expand the network from five health hubs to 13 across the state by the end o.

defenseworld.net2026-07-29

UnitedHealth Group Incorporated $UNH Stake Lowered by Amundi

Amundi lowered its position in shares of UnitedHealth Group Incorporated (NYSE: UNH) by 13.3% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 6,376,198 shares of the healthcare conglomerate's stock after selling 979,859 shares during the period. Amundi owned 0.70% of UnitedHealth Group worth $1,725,334,000 as

invezz.com2026-07-28

Wolfe says buy these three quality stocks into post-earnings strength

July has dealt Wall Street a turbulent hand. US stocks have drifted lower this month, hampered by persistent geopolitical risks, rising crude oil prices, and mounting anxiety over rising AI capex.

fool.com2026-07-28

UnitedHealth Stock Has Rallied Big Since Berkshire Bailed. Did Warren Buffett and Greg Abel Blink Too Soon?

Berkshire bought UnitedHealth stock a year ago and sold it at a loss in the first quarter. The company is beginning to see a recovery in its profit margins, which is driving the stock higher.

fool.com2026-07-28

3 Dividend Stocks That Are Crushing the Market in 2026

These stocks are all up more than 28% this year.

zacks.com2026-07-27

UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch

UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

defenseworld.net2026-07-27

6,050 Shares in UnitedHealth Group Incorporated $UNH Acquired by Delta Global Management LP

Delta Global Management LP acquired a new stake in shares of UnitedHealth Group Incorporated (NYSE: UNH) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 6,050 shares of the healthcare conglomerate's stock, valued at approximately $1,637,000. Other institutional investors also recently bought and sold shares of

zacks.com2026-07-24

Is Trending Stock UnitedHealth Group Incorporated (UNH) a Buy Now?

UnitedHealth (UNH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com2026-07-24

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

zacks.com2026-07-23

Here's Why UnitedHealth Group (UNH) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"UNH reported Q2 2026 results with Revenue of $112.0B and Net Income of $5.48B, delivering EPS of $6.05. QoQ (vs. 2026-03-31) Revenue rose slightly by +0.3% ($112.032B vs. $111.721B) while Net Income declined by -12.7% ($5.48B vs. $6.28B). YoY (vs. 2025-06-30) Revenue was up +0.4% ($112.032B vs. $111.616B) and Net Income increased by +61.0% ($5.48B vs. $3.41B). Profitability is mixed: gross profit margin improved sequentially (32.7% vs. 22.7%) but net margin contracted QoQ (4.90% vs. 5.62%), and operating margin slipped (7.13% vs. 8.05%), indicating cost/other line volatility. Cash generation remained strong in the quarter: operating cash flow was $11.05B and free cash flow was $10.25B, which comfortably covered dividends of $2.09B. Balance sheet resilience remains solid for a non-bank: total assets were $309.7B with equity of ~$106.0B, though equity and cash declined from Q1. Total shareholder returns are currently pressured: the stock is down -44.5% over 1 year (capital depreciation), partially offset by a low dividend yield (~0.8%). With no strong 1Y price momentum, the “shareholder returns” component is capped despite solid earnings/cash quality."

Revenue Growth

Positive

Revenue was up slightly QoQ (+0.3%) and modestly YoY (+0.4%), indicating stable top-line with no acceleration.

Profitability

Fair

Net margin fell QoQ (4.90% vs. 5.62%) and operating margin declined (7.13% vs. 8.05%), though YoY net income jumped (+61%) suggesting earnings benefited from year-over-year item swings.

Cash Flow Quality

Good

Operating cash flow was $11.05B and free cash flow $10.25B in Q2 2026; dividends of $2.09B appear well covered by free cash flow.

Leverage & Balance Sheet

Neutral

Total assets were $309.7B and equity was ~$106.0B. Liquidity eased vs. Q1 (cash down) but the balance sheet remains broadly resilient.

Shareholder Returns

Neutral

1-year price performance is weak (-44.5%), and the dividend yield is low (~0.8%), so total return is likely negative despite buyback/dividend support signals in cash flow.

Analyst Sentiment & Valuation

Neutral

Current price ($324.63) is below the consensus target (459.12), implying potential upside, though recent momentum is unfavorable given the sharp 1Y decline.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

UNH delivered a strong Q2 with adjusted EPS of $6.38 (up from $4.08) and $112B revenue, supported by $860M favorable prior-period medical development and disciplined operating costs despite a higher operating cost ratio (12.7%). Guidance was refreshed upward for full-year adjusted EPS to $19.50–$20 and raised operating earnings to at least $12B for UnitedHealthcare and $2.2B for Optum Health. The key swing factor is mix: Medicare Advantage trend is below planning assumptions and Medicare margins are guided above 3%, but management stressed no “inflection” because underlying medical cost trends remain elevated vs historical levels. Commercial remains the largest headwind, with cost trend modestly above 11% driven by No Surprises Act IDR exploitation (~50 bps incremental trend; at least ~100 bps total cost impact), provider coding intensity, and specialty pharmacy (including GLP-1s). Capital return accelerated (buyback guidance at least $5B), while Optum continues progressing in AI-enabled workflows and integrated value-based care delivery.

AI IconGrowth Catalysts

  • Medicare Advantage benefit planning/benefit design and network curation driving better-than-expected Q2 results and improved full-year outlook
  • Optum Health recentering into integrated value-based care delivery model improving care management and operating discipline
  • Optum Rx transparency initiatives supporting retention in the high 90s and progress toward 100% manufacturer rebate pass-through
  • Optum Insight AI-enabled products (e.g., AI-enabled coding, real-time payer/provider interfaces, clinical quality/safety support) gaining traction with customers

Business Development

  • Closed combination with Alegeus on July 2, 2026
  • Optum Rx: new pharmacy care approach announced in May based on monthly per-member fees with full PBM and GPO fee transparency and enhanced consumer tools
  • Optum Health: expanded house calls/home-based care with treat-in-place offerings for complex chronic/behavioral health conditions; reaches nearly 90% of U.S. counties

AI IconFinancial Highlights

  • Adjusted EPS: $6.38 vs $4.08 prior year; Total revenues: $112B (largely flat YoY); Operating earnings: $8B, +55% YoY
  • Medical care ratio (reported) 86.7% includes $860M net favorable prior period medical development (vs 89.4% in 2Q 2025); days claims payable 47 days (+~2.5 days YoY); operating cost ratio 12.7% vs 12.3% a year ago
  • Guidance updated: full-year adjusted EPS $19.50–$20 (slightly more earnings in Q3 than Q4)
  • Full-year medical care ratio guidance: 88.1% ±25 bps
  • Full-year operating earnings outlook raised to at least $12B for UnitedHealthcare and at least $2.2B for Optum Health
  • Capital return/balance sheet: repurchases deployed $4B through mid-July; repurchases guidance increased to at least $5B in 2026 (from initial $2.5B)
  • Debt ratio: debt to capital 41.2% at quarter-end (vs 44.1% one year ago; +170 bps sequential improvement vs Q1); target ~40% by end of 2026

AI IconCapital Funding

  • Share repurchases: $4.0B deployed through mid-July for 11.4M shares
  • 2026 total buyback: at least $5B (raised from initial $2.5B guidance)
  • Dividends: $2.1B returned in the quarter; board increased annualized dividend to $9.28 per share
  • Balance sheet: debt to capital 41.2% at quarter-end with target ~40% by end of 2026

AI IconStrategy & Ops

  • UnitedHealthcare: committed by end of 2026 to eliminate 30% of prior authorization volume and nearly two-thirds of prior authorization requirements for pediatric care
  • Operational/routing experience focus areas: care approvals, information accuracy, speed of response, access/scheduling, digital services, and care path navigation
  • Optum Health: AI-based ambient listening rollout—70% of employed providers as of the quarter; on track to exceed 90% by year-end
  • Optum Health clinical outcomes: ~10% reduction in hospitalizations since late last year in Western/Southern regions; home health pilots improved timely care delivery >20%, reduced acute utilization, and shorter skilled nursing facility stays
  • Optum Rx: targeted pass-through commitment—expect end of 2026 with >95% of clients on 100% pass-through; ongoing transparency and fee-based services shift

AI IconMarket Outlook

  • 2026 Medicare medical cost trend expected below initial estimate of ~10%
  • Medicare Advantage: now expects full-year enrollment decline of ~1.1M and Medicare margins finishing 2026 above 3%
  • 2026 Medicaid: rate actions expected annualized impacts ~6%–7% (still lagging elevated medical trend) with margins within previously communicated -1% to -1.7% range
  • Commercial: medical cost trends modestly above 11% level previously seen/expected
  • Earnings cadence: UnitedHealthcare ~75% of earnings recognized in first half; Optum Health nearly all in first half (modest Q3 profit; modest Q4 losses from risk-based seasonality); Optum Insight and Optum Rx ~55% of earnings in back half

AI IconRisks & Headwinds

  • Medicare trend remains high vs historical levels despite coming in below planning assumptions; management stated no “inflection point” in trend—continuation at elevated levels
  • Commercial margins face delayed recovery: No Surprises Act independent resolution process being exploited by select providers/geographies contributing ~50 bps of incremental trend (total at least ~100 bps of total cost contribution attributed to the mechanism); provider coding intensity and specialty drug costs (including anti-inflammatories and GLP-1s) adding pressure; limited offset from utilization/pattern pullback
  • Medicaid margins pressured for 2026 due to reimbursement lag vs underlying medical cost trends; trend pressure persists in specialty pharmacy, home and community-based services, behavioral healthcare, and increased inpatient SNF costs for complex populations
  • Prior period development may be a factor in reported metrics (medical care ratio includes $860M favorable prior period medical development in the quarter)

Q&A: Analyst Interest

  • Medicaid margin and end-of-year outcome: Management said Q2 Medicaid was in line with expectations, benefiting from affordability actions (network curation, payment integrity, fraud/waste/abuse, and operating cost disciplines). Trend remains elevated vs pre-pandemic but stable, with continued pressure in specialty pharmacy, HCS/behavioral health, and some SNF inpatient costs. They expect annualized 2026 rate impacts ~6%–7% and margins within the previously communicated -1% to -1.7% range.
  • Commercial cost trend drivers and margin trajectory vs prior assumptions: Management attributed the modestly-above-11% trend to No Surprises Act IDR exploitation by select providers/geographies (~50 bps incremental trend; at least ~100 bps total cost contribution), plus provider coding intensity at office visits/ED and certain sites. Pharmacy (specialty drugs, including anti-inflammatory and GLP-1s) added pressure; no meaningful utilization/category offsets observed. They framed 2026 as a delay (not a setback) to margin recovery, implying full commercial historic 7%+ margins may extend beyond 2027.
  • Medicare Advantage medical cost trend vs bid/planning assumptions: Management explained that while trend remains very high versus historical levels across products, Medicare is running lower than benefit-planning assumptions. They emphasized this is not an inflection; it still stays at elevated levels but improves relative to initial planning. They cited positive claims/respiratory season/weather impacts and targeted actions (benefit design, product positioning/mix, network curation, and affordability/value-based aligned provider models), and stated 2027 bidding remains too early for specifics.

Sentiment: MIXED

Note: This summary was synthesized by AI from the UNH Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for UNH.

SEC EDGAR Live Feed
No recent 10-K available.
No recent 10-Q available.
Loading financial data and tables...
📁

SEC Filings (UNH)

© 2026 Stock Market Info — UnitedHealth Group Incorporated (UNH) Financial Profile